209 related articles for article (PubMed ID: 21941623)
61. A solution to limited genomic capacity: using adaptable binding surfaces to assemble the functional HIV Rev oligomer on RNA.
Daugherty MD; D'Orso I; Frankel AD
Mol Cell; 2008 Sep; 31(6):824-34. PubMed ID: 18922466
[TBL] [Abstract][Full Text] [Related]
62. Dynamic ensemble of HIV-1 RRE stem IIB reveals non-native conformations that disrupt the Rev-binding site.
Chu CC; Plangger R; Kreutz C; Al-Hashimi HM
Nucleic Acids Res; 2019 Jul; 47(13):7105-7117. PubMed ID: 31199872
[TBL] [Abstract][Full Text] [Related]
63. A small-molecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference.
Prado S; Beltrán M; Moreno Á; Bedoya LM; Alcamí J; Gallego J
Biochem Pharmacol; 2018 Oct; 156():68-77. PubMed ID: 30071201
[TBL] [Abstract][Full Text] [Related]
64. Comparative analysis of RNA/protein dynamics for the arginine-rich-binding motif and zinc-finger-binding motif proteins encoded by HIV-1.
Wang H; Ma X; Yeh YS; Zhu Y; Daugherty MD; Frankel AD; Musier-Forsyth K; Barbara PF
Biophys J; 2010 Nov; 99(10):3454-62. PubMed ID: 21081095
[TBL] [Abstract][Full Text] [Related]
65. Computational investigation of the HIV-1 Rev multimerization using molecular dynamics simulations and binding free energy calculations.
Venken T; Daelemans D; De Maeyer M; Voet A
Proteins; 2012 Jun; 80(6):1633-46. PubMed ID: 22447650
[TBL] [Abstract][Full Text] [Related]
66. The simian retrovirus-1 constitutive transport element, unlike the HIV-1 RRE, uses factors required for cellular mRNA export.
Saavedra C; Felber B; Izaurralde E
Curr Biol; 1997 Sep; 7(9):619-28. PubMed ID: 9285715
[TBL] [Abstract][Full Text] [Related]
67. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1.
DeJong ES; Chang CE; Gilson MK; Marino JP
Biochemistry; 2003 Jul; 42(26):8035-46. PubMed ID: 12834355
[TBL] [Abstract][Full Text] [Related]
68. Exploring the HIV-1 Rev Recognition Element (RRE)-Rev Inhibitory Capacity and Antiretroviral Action of Benfluron Analogs.
Chumillas S; Loharch S; Beltrán M; Szewczyk MP; Bernal S; Puertas MC; Martinez-Picado J; Alcamí J; Bedoya LM; Marchán V; Gallego J
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894510
[TBL] [Abstract][Full Text] [Related]
69. Randomized codon mutagenesis reveals that the HIV Rev arginine-rich motif is robust to substitutions and that double substitution of two critical residues alters specificity.
Possik EJ; Bou Sleiman MS; Ghattas IR; Smith CA
J Mol Recognit; 2013 Jun; 26(6):286-96. PubMed ID: 23595810
[TBL] [Abstract][Full Text] [Related]
70. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids.
Olsen HS; Cochrane AW; Dillon PJ; Nalin CM; Rosen CA
Genes Dev; 1990 Aug; 4(8):1357-64. PubMed ID: 2227413
[TBL] [Abstract][Full Text] [Related]
71. Phenotypic analysis of human immunodeficiency virus type 1 Rev trimerization-interface mutants in human cells.
Trikha R; Brighty DW
J Gen Virol; 2005 May; 86(Pt 5):1509-1513. PubMed ID: 15831964
[TBL] [Abstract][Full Text] [Related]
72. Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen.
Prado S; Beltrán M; Coiras M; Bedoya LM; Alcamí J; Gallego J
Biochem Pharmacol; 2016 May; 107():14-28. PubMed ID: 26896646
[TBL] [Abstract][Full Text] [Related]
73. Rev regulates translation of human immunodeficiency virus type 1 RNAs.
Groom HCT; Anderson EC; Dangerfield JA; Lever AML
J Gen Virol; 2009 May; 90(Pt 5):1141-1147. PubMed ID: 19264599
[TBL] [Abstract][Full Text] [Related]
74. Mechanism of neomycin and Rev peptide binding to the Rev responsive element of HIV-1 as determined by fluorescence and NMR spectroscopy.
Lacourciere KA; Stivers JT; Marino JP
Biochemistry; 2000 May; 39(19):5630-41. PubMed ID: 10801313
[TBL] [Abstract][Full Text] [Related]
75. CRNKL1 Is a Highly Selective Regulator of Intron-Retaining HIV-1 and Cellular mRNAs.
Xiao H; Wyler E; Milek M; Grewe B; Kirchner P; Ekici A; Silva ABOV; Jungnickl D; Full F; Thomas M; Landthaler M; Ensser A; Überla K
mBio; 2021 Jan; 12(1):. PubMed ID: 33468685
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
Lee SW; Gallardo HF; Gilboa E; Smith C
J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
[TBL] [Abstract][Full Text] [Related]
77. Trimethylguanosine capping selectively promotes expression of Rev-dependent HIV-1 RNAs.
Yedavalli VS; Jeang KT
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14787-92. PubMed ID: 20679221
[TBL] [Abstract][Full Text] [Related]
78. Rev-ing up post-transcriptional HIV-1 RNA expression.
Yedavalli VS; Jeang KT
RNA Biol; 2011; 8(2):195-9. PubMed ID: 21358275
[TBL] [Abstract][Full Text] [Related]
79. Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle.
Fischer U; Pollard VW; Lührmann R; Teufel M; Michael MW; Dreyfuss G; Malim MH
Nucleic Acids Res; 1999 Nov; 27(21):4128-34. PubMed ID: 10518602
[TBL] [Abstract][Full Text] [Related]
80. Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells.
Stauber RH; Afonina E; Gulnik S; Erickson J; Pavlakis GN
Virology; 1998 Nov; 251(1):38-48. PubMed ID: 9813201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
